Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope & definitions
1.3 Base estimates & working
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Active Pharmaceutical Ingredients industry 3600 synopsis, 2018-2032
2.1.1 Business trends
2.1.2 Therapeutic category trends
2.1.3 Synthesis type trends
2.1.4 Contract outsourcing type trends
2.1.5 Application trends
2.1.6 Drug type trends
2.1.7 Regional trends
Chapter 3 Active Pharmaceutical Ingredients Industry Insights
3.1 Industry landscape, 2018-2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of chronic diseases
3.2.1.2 Rising drug research and development activities
3.2.1.3 Increasing demand for generics
3.2.1.4 Increasing uptake of biopharmaceuticals
3.2.2 Industry pitfalls & challenges
3.2.2.1 Unfavourable drug price control policies
3.2.2.2 High manufacturing costs
3.3 Growth potential analysis
3.3.1 By therapeutic category trends
3.3.2 By synthesis type trends
3.3.3 By contract outsourcing type trends
3.3.4 By application trends
3.3.5 By drug type trends
3.4 COVID-19 impact analysis
3.5 Technology landscape
3.6 Supply chain analysis
3.7 key market trends
3.8 Pipeline analysis
3.9 Regulatory landscape
3.9.1 U.S.
3.9.2 Europe
3.9.3 Asia Pacific
3.10 Vendor matrix analysis
3.11 API manufacturing trends
3.12 Overview of API Production
3.12.1 Share of supply in (%) Total European Demand in Tons
3.12.2 Overview of CEPS, APIs and Manufacturers By Region (2000-2020)
3.12.3 Overview of development of the number of valid CEPS (2000 -2020)
3.12.4 Overview of global distribution of currently valid CEPS (2020)
3.12.5 Analyst insights
3.13 Policy landscape
3.13.1 China
3.13.2 India
3.14 Porter's analysis
3.15 PESTEL analysis
Chapter 4 Competitive Landscape, 2021
4.1 Introduction
4.2 Company matrix analysis, 2021
4.3 Strategy dashboard, 2021
4.4 Strategy landscape
Chapter 5 Active Pharmaceutical Ingredients Market, By Therapeutic Category
5.1 Key therapeutic category trends
5.2 Oncology
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Infectious diseases
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4 Anti-diabetics
5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.5 CNS & anesthesia
5.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.6 Cardiovascular diseases
5.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.7 Biologics
5.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.8 Others
5.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Active Pharmaceutical Ingredients Market, By Synthesis Type
6.1 Key synthesis type trends
6.2 Chemical based API
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Biological API
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Highly potent API (HPAPI)
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Active Pharmaceutical Ingredients Market, By Contract Outsourcing Type
7.1 Key contract outsourcing type trends
7.2 CDMO
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 CMO
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Active Pharmaceutical Ingredients Market, By Application
8.1 Key application trends
8.2 Humans
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Veterinary
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Active Pharmaceutical Ingredients Market, By Drug Type
9.1 Key drug type trends
9.2 Prescription
9.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
9.3 OTC
9.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 10 Active Pharmaceutical Ingredients Market, By Region
10.1 Key regional trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Switzerland
10.3.2 France
10.3.3 Italy
10.3.4 Germany
10.3.5 UK
10.3.6 Spain
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Vietnam
10.4.7 Indonesia
10.4.8 Thailand
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Colombia
10.5.5 Chile
10.5.6 Peru
10.6 MEA
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Qatar
10.6.5 Bahrain
10.6.6 Egypt
Chapter 11 Company Profiles
11.1 Merck & Co., Inc.
11.2 Aarti Drugs Ltd
11.3 Biocon Ltd.
11.4 Qilu Pharmaceutical Co., Ltd.
11.5 Divi's Laboratories Limited
11.6 EUROAPI
11.7 Hikal Ltd.
11.8 Teva Pharmaceutical Industries Ltd
11.9 Cipla Ltd.
11.10 Neuland Laboratories Ltd.
11.11 Aurobindo Pharma Ltd
11.12 Sun Pharmaceutical Industries Ltd.
11.13 Dr. Reddy’s Laboratories Ltd
11.14 Pfizer, Inc
11.15 Solara Active Pharma
11.16 Alivira Animal Health Ltd
11.17 SUANFARMA
11.18 Procyon Life Sciences
11.19 NGL Fine-Chem Ltd
11.20 Ofichem Group
